<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/C0805014-A6FD-41C1-81BE-B94AE4139F25"><gtr:id>C0805014-A6FD-41C1-81BE-B94AE4139F25</gtr:id><gtr:name>Max Planck Society</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/CB0C90CF-B277-4BCB-B3EE-2214E203AB68"><gtr:id>CB0C90CF-B277-4BCB-B3EE-2214E203AB68</gtr:id><gtr:name>Cybula</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/F11E21C9-E05F-4173-939C-61F868FE1FBA"><gtr:id>F11E21C9-E05F-4173-939C-61F868FE1FBA</gtr:id><gtr:name>The Wellcome Trust Ltd</gtr:name><gtr:address><gtr:line1>215 Euston Road</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>NW1 2BE</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/47CC4050-87A9-4965-B949-35C9C52402DA"><gtr:id>47CC4050-87A9-4965-B949-35C9C52402DA</gtr:id><gtr:name>Pharmidex</gtr:name><gtr:address><gtr:line1>Pharmidex</gtr:line1><gtr:line2>72 New Bond Street</gtr:line2><gtr:line3>Mayfair</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>W15 1RR</gtr:postCode><gtr:region>Unknown</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/AEB9ABF8-53AE-4FFB-B851-B61B91AD4154"><gtr:id>AEB9ABF8-53AE-4FFB-B851-B61B91AD4154</gtr:id><gtr:name>ProBioGen AG</gtr:name><gtr:address><gtr:line1>Goethestr 54</gtr:line1><gtr:postCode>13086</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/A88086FE-C28F-4863-8B2B-1A97734A6C79"><gtr:id>A88086FE-C28F-4863-8B2B-1A97734A6C79</gtr:id><gtr:name>University of Strasbourg</gtr:name><gtr:address><gtr:line1>Universite Louis Pasteur</gtr:line1><gtr:line2>4 rue Blaise Pascal</gtr:line2><gtr:line4>Strasbourg</gtr:line4><gtr:line5>Cedex</gtr:line5><gtr:postCode>67070</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>France</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/5ABCC373-8D79-4794-9EAD-C1BAFAA2F5D7"><gtr:id>5ABCC373-8D79-4794-9EAD-C1BAFAA2F5D7</gtr:id><gtr:name>Milenia Biotec GmbH</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/3C4A98AE-E216-488D-ABD5-B21CD9B10326"><gtr:id>3C4A98AE-E216-488D-ABD5-B21CD9B10326</gtr:id><gtr:name>Institute for Endemic Diseases IEND</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/FDA3FC4C-8E75-4C67-9DA6-3482A4A94186"><gtr:id>FDA3FC4C-8E75-4C67-9DA6-3482A4A94186</gtr:id><gtr:name>Drugs for Neglected Diseases initiative (DNDi)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/055EA8B7-2C66-4FF5-96DD-63FA3AA7D0B7"><gtr:id>055EA8B7-2C66-4FF5-96DD-63FA3AA7D0B7</gtr:id><gtr:name>London Sch of Hygiene and Trop Medicine</gtr:name><gtr:address><gtr:line1>Keppel Street</gtr:line1><gtr:postCode>WC1E 7HT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/C26EC5DC-44D6-4728-8540-416E1CC7A2CB"><gtr:id>C26EC5DC-44D6-4728-8540-416E1CC7A2CB</gtr:id><gtr:name>University of Lisbon</gtr:name><gtr:address><gtr:line1>Campo Grande</gtr:line1><gtr:line2>Edificio C5</gtr:line2><gtr:line3>1749-016</gtr:line3><gtr:region>Unknown</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/818CD6C9-61EE-41F2-9F37-0C7A8F43E25D"><gtr:id>818CD6C9-61EE-41F2-9F37-0C7A8F43E25D</gtr:id><gtr:name>University of Birmingham</gtr:name><gtr:address><gtr:line1>Edgbaston Park Road</gtr:line1><gtr:line2>Edgbaston</gtr:line2><gtr:postCode>B15 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/CB1913B8-C3D1-4B1D-B5F8-0A0DE86A12CE"><gtr:id>CB1913B8-C3D1-4B1D-B5F8-0A0DE86A12CE</gtr:id><gtr:name>Silence Therapeutics</gtr:name><gtr:address><gtr:line1>72 Hammersmith Road</gtr:line1><gtr:postCode>W14 8TH</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/72297581-AFDA-4A4D-95A7-EED105B2675F"><gtr:id>72297581-AFDA-4A4D-95A7-EED105B2675F</gtr:id><gtr:name>Federal University of Pelotas</gtr:name><gtr:address><gtr:line1>Campus Porto, Caixa Postal 354</gtr:line1><gtr:region>Unknown</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/D317E8C1-3E16-4E48-8AAC-E2A0961F5299"><gtr:id>D317E8C1-3E16-4E48-8AAC-E2A0961F5299</gtr:id><gtr:name>Erasmus University Medical Center</gtr:name><gtr:address><gtr:line1>PO Box 2040</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>Netherlands</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/02E332A3-D1B0-4439-88A6-04F88D53552E"><gtr:id>02E332A3-D1B0-4439-88A6-04F88D53552E</gtr:id><gtr:name>Sim Omics</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/5EFEC12E-A713-436C-BC10-5931E15AB073"><gtr:id>5EFEC12E-A713-436C-BC10-5931E15AB073</gtr:id><gtr:name>Federal University of Rio de Janeiro</gtr:name><gtr:address><gtr:line1>Av Brigadeiro Trompowski s/no</gtr:line1><gtr:line2>Predio da Reitoria, 2o andar</gtr:line2><gtr:line3>Cidade Universitaria</gtr:line3><gtr:line4>Rio de Janeiro</gtr:line4><gtr:line5>RJ - CEP 21941-590</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Brazil</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/7FF2A05C-1CC6-4062-87EC-37851A449DC1"><gtr:id>7FF2A05C-1CC6-4062-87EC-37851A449DC1</gtr:id><gtr:name>Institute of Postgraduate Medical Education and Research (IPGME&amp;R)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/CAE05735-49AC-4F8D-A98E-059A8CE92654"><gtr:id>CAE05735-49AC-4F8D-A98E-059A8CE92654</gtr:id><gtr:name>Materiomics</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/E3FF571C-4ECF-478A-AA19-5F68DA0D9627"><gtr:id>E3FF571C-4ECF-478A-AA19-5F68DA0D9627</gtr:id><gtr:name>University of Zurich</gtr:name><gtr:address><gtr:line1>71,Raemistrasse</gtr:line1><gtr:line4>Zurich</gtr:line4><gtr:line5>CH 8006</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Switzerland</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/68D0E3C9-9246-4CFC-B5E9-48584CF82993"><gtr:id>68D0E3C9-9246-4CFC-B5E9-48584CF82993</gtr:id><gtr:name>University of Manchester</gtr:name><gtr:address><gtr:line1>Oxford Road</gtr:line1><gtr:city>Manchester</gtr:city><gtr:postCode>M13 9PL</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/2BD9D58B-192A-4FFE-A393-CA97F2F9AC43"><gtr:id>2BD9D58B-192A-4FFE-A393-CA97F2F9AC43</gtr:id><gtr:name>Institute of Immunobiology</gtr:name><gtr:address><gtr:line1>Dr Rudolphs Lab</gtr:line1><gtr:line2>Max Plancks</gtr:line2><gtr:line3>St?beweg 51</gtr:line3><gtr:postCode>79104</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/8319F78A-DCBD-49F6-BE00-78E1CD75CDA9"><gtr:id>8319F78A-DCBD-49F6-BE00-78E1CD75CDA9</gtr:id><gtr:name>University of York</gtr:name><gtr:department>Biology</gtr:department><gtr:address><gtr:line1>Heslington</gtr:line1><gtr:line4>York</gtr:line4><gtr:line5>North Yorkshire</gtr:line5><gtr:postCode>YO10 5DD</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/8319F78A-DCBD-49F6-BE00-78E1CD75CDA9"><gtr:id>8319F78A-DCBD-49F6-BE00-78E1CD75CDA9</gtr:id><gtr:name>University of York</gtr:name><gtr:address><gtr:line1>Heslington</gtr:line1><gtr:line4>York</gtr:line4><gtr:line5>North Yorkshire</gtr:line5><gtr:postCode>YO10 5DD</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/C0805014-A6FD-41C1-81BE-B94AE4139F25"><gtr:id>C0805014-A6FD-41C1-81BE-B94AE4139F25</gtr:id><gtr:name>Max Planck Society</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/CB0C90CF-B277-4BCB-B3EE-2214E203AB68"><gtr:id>CB0C90CF-B277-4BCB-B3EE-2214E203AB68</gtr:id><gtr:name>Cybula</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/A88086FE-C28F-4863-8B2B-1A97734A6C79"><gtr:id>A88086FE-C28F-4863-8B2B-1A97734A6C79</gtr:id><gtr:name>University of Strasbourg</gtr:name><gtr:address><gtr:line1>Universite Louis Pasteur</gtr:line1><gtr:line2>4 rue Blaise Pascal</gtr:line2><gtr:line4>Strasbourg</gtr:line4><gtr:line5>Cedex</gtr:line5><gtr:postCode>67070</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>France</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/72297581-AFDA-4A4D-95A7-EED105B2675F"><gtr:id>72297581-AFDA-4A4D-95A7-EED105B2675F</gtr:id><gtr:name>Federal University of Pelotas</gtr:name><gtr:address><gtr:line1>Campus Porto, Caixa Postal 354</gtr:line1><gtr:region>Unknown</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/02E332A3-D1B0-4439-88A6-04F88D53552E"><gtr:id>02E332A3-D1B0-4439-88A6-04F88D53552E</gtr:id><gtr:name>Sim Omics</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/7FF2A05C-1CC6-4062-87EC-37851A449DC1"><gtr:id>7FF2A05C-1CC6-4062-87EC-37851A449DC1</gtr:id><gtr:name>Institute of Postgraduate Medical Education and Research (IPGME&amp;R)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/F11E21C9-E05F-4173-939C-61F868FE1FBA"><gtr:id>F11E21C9-E05F-4173-939C-61F868FE1FBA</gtr:id><gtr:name>The Wellcome Trust Ltd</gtr:name><gtr:address><gtr:line1>215 Euston Road</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>NW1 2BE</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/47CC4050-87A9-4965-B949-35C9C52402DA"><gtr:id>47CC4050-87A9-4965-B949-35C9C52402DA</gtr:id><gtr:name>Pharmidex</gtr:name><gtr:address><gtr:line1>Pharmidex</gtr:line1><gtr:line2>72 New Bond Street</gtr:line2><gtr:line3>Mayfair</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>W15 1RR</gtr:postCode><gtr:region>Unknown</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/AEB9ABF8-53AE-4FFB-B851-B61B91AD4154"><gtr:id>AEB9ABF8-53AE-4FFB-B851-B61B91AD4154</gtr:id><gtr:name>ProBioGen AG</gtr:name><gtr:address><gtr:line1>Goethestr 54</gtr:line1><gtr:postCode>13086</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/5ABCC373-8D79-4794-9EAD-C1BAFAA2F5D7"><gtr:id>5ABCC373-8D79-4794-9EAD-C1BAFAA2F5D7</gtr:id><gtr:name>Milenia Biotec GmbH</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/3C4A98AE-E216-488D-ABD5-B21CD9B10326"><gtr:id>3C4A98AE-E216-488D-ABD5-B21CD9B10326</gtr:id><gtr:name>Institute for Endemic Diseases IEND</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/FDA3FC4C-8E75-4C67-9DA6-3482A4A94186"><gtr:id>FDA3FC4C-8E75-4C67-9DA6-3482A4A94186</gtr:id><gtr:name>Drugs for Neglected Diseases initiative (DNDi)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/055EA8B7-2C66-4FF5-96DD-63FA3AA7D0B7"><gtr:id>055EA8B7-2C66-4FF5-96DD-63FA3AA7D0B7</gtr:id><gtr:name>London Sch of Hygiene and Trop Medicine</gtr:name><gtr:address><gtr:line1>Keppel Street</gtr:line1><gtr:postCode>WC1E 7HT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/C26EC5DC-44D6-4728-8540-416E1CC7A2CB"><gtr:id>C26EC5DC-44D6-4728-8540-416E1CC7A2CB</gtr:id><gtr:name>University of Lisbon</gtr:name><gtr:address><gtr:line1>Campo Grande</gtr:line1><gtr:line2>Edificio C5</gtr:line2><gtr:line3>1749-016</gtr:line3><gtr:region>Unknown</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/818CD6C9-61EE-41F2-9F37-0C7A8F43E25D"><gtr:id>818CD6C9-61EE-41F2-9F37-0C7A8F43E25D</gtr:id><gtr:name>University of Birmingham</gtr:name><gtr:address><gtr:line1>Edgbaston Park Road</gtr:line1><gtr:line2>Edgbaston</gtr:line2><gtr:postCode>B15 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/CB1913B8-C3D1-4B1D-B5F8-0A0DE86A12CE"><gtr:id>CB1913B8-C3D1-4B1D-B5F8-0A0DE86A12CE</gtr:id><gtr:name>Silence Therapeutics</gtr:name><gtr:address><gtr:line1>72 Hammersmith Road</gtr:line1><gtr:postCode>W14 8TH</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/D317E8C1-3E16-4E48-8AAC-E2A0961F5299"><gtr:id>D317E8C1-3E16-4E48-8AAC-E2A0961F5299</gtr:id><gtr:name>Erasmus University Medical Center</gtr:name><gtr:address><gtr:line1>PO Box 2040</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>Netherlands</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/5EFEC12E-A713-436C-BC10-5931E15AB073"><gtr:id>5EFEC12E-A713-436C-BC10-5931E15AB073</gtr:id><gtr:name>Federal University of Rio de Janeiro</gtr:name><gtr:address><gtr:line1>Av Brigadeiro Trompowski s/no</gtr:line1><gtr:line2>Predio da Reitoria, 2o andar</gtr:line2><gtr:line3>Cidade Universitaria</gtr:line3><gtr:line4>Rio de Janeiro</gtr:line4><gtr:line5>RJ - CEP 21941-590</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Brazil</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/CAE05735-49AC-4F8D-A98E-059A8CE92654"><gtr:id>CAE05735-49AC-4F8D-A98E-059A8CE92654</gtr:id><gtr:name>Materiomics</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/E3FF571C-4ECF-478A-AA19-5F68DA0D9627"><gtr:id>E3FF571C-4ECF-478A-AA19-5F68DA0D9627</gtr:id><gtr:name>University of Zurich</gtr:name><gtr:address><gtr:line1>71,Raemistrasse</gtr:line1><gtr:line4>Zurich</gtr:line4><gtr:line5>CH 8006</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Switzerland</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/68D0E3C9-9246-4CFC-B5E9-48584CF82993"><gtr:id>68D0E3C9-9246-4CFC-B5E9-48584CF82993</gtr:id><gtr:name>University of Manchester</gtr:name><gtr:address><gtr:line1>Oxford Road</gtr:line1><gtr:city>Manchester</gtr:city><gtr:postCode>M13 9PL</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/2BD9D58B-192A-4FFE-A393-CA97F2F9AC43"><gtr:id>2BD9D58B-192A-4FFE-A393-CA97F2F9AC43</gtr:id><gtr:name>Institute of Immunobiology</gtr:name><gtr:address><gtr:line1>Dr Rudolphs Lab</gtr:line1><gtr:line2>Max Plancks</gtr:line2><gtr:line3>St?beweg 51</gtr:line3><gtr:postCode>79104</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/774D2A5D-D3BA-47D3-BBEF-1D7CFDCB9AB6"><gtr:id>774D2A5D-D3BA-47D3-BBEF-1D7CFDCB9AB6</gtr:id><gtr:firstName>Paul</gtr:firstName><gtr:otherNames>Martin</gtr:otherNames><gtr:surname>Kaye</gtr:surname><gtr:orcidId>0000-0002-8796-4755</gtr:orcidId><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G1000230"><gtr:id>FB5D8ADE-CB7E-4C9A-9AE0-5020C2A0852E</gtr:id><gtr:title>Immunology and Immunopathology of visceral leishmaniasis</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G1000230</gtr:grantReference><gtr:abstractText>Leishmaniasis is a disease caused when people are bitten by sandflies that contain a small single cell parasite, called Leishmania. Although some people never get sick, many develop local skin ulcers or a potentially fatal disease that affects the internal organs, called visceral leishmaniasis (kala azar or ?black sickness?). Why different people get different types of disease is not known, but it may relate to the type of Leishmania they are infected with and their health of their immune system. 2 million people get leishmaniasis every year (in 88 countries, including some in Europe) and visceral leishmaniasis is responsible for over 60,000 deaths annually. As the parasites live deep in the tissues (spleen, liver, bone marrow), it is difficult in sick people to see exactly how they are affecting our immune system and to find ways to improve how the immune system deals with them. Therefore, we need to use experimental models of the disease to study these questions. Although much progress has been made, experimental models cannot provide the whole picture and there may be important differences in how mice and people respond to these parasites, or in how much damage the immune system does to our organs trying to fight the infection. We wish to conduct an integrated research programme to let us study disease processes in human and mouse tissues side by side. This approach is important, both to see whether the responses in mice also occur in man (thus supporting clinical study of drugs/vaccines developed in mice) and conversely to see whether we can improve the predictive nature of models used for testing drugs/vaccines. We will be studying how Leishmania is eaten by white blood cells (phagocytes) in the liver, and how the expression of our genes changes in response to the infection. We will develop new microscopy approaches that allow us to see how infection affects phagocyte function and their ability to coordinate inflammation. We will use tissues samples taken from people during treatment and also at post mortem, to observe how well their immune systems have responded to treatment or to understand what went wrong that led to their death. In combination, these studies will provide much important new information on human disease, and help to reduce and improve the quality of animal experimentation.</gtr:abstractText><gtr:technicalSummary>Leishmaniasis represents a spectrum of diseases associated with infection by the protozoan parasite, Leishmania. Of global importance, with approximately 2M new cases reported annually from 88 countries, leishmaniasis ranks high amongst parasitic diseases for its impact on public health. Visceral leishmaniasis (VL), caused by L. donovani and L. infantum/chagasi is a leading cause of parasite-associated mortality. Research on VL thus holds potential for major benefits to health. In addition, the study of this intracellular parasite continues to increase our fundamental understanding of the host-parasite interface and immune function. Building on the exciting achievements of our previous MRC supported research, we now seek to develop a fully-integrated programme, using animal models, human liver-slice culture and clinical histopathology, to explore the diverse roles played by mononuclear phagocytes in VL (as host, regulator of inflammation / immunity, and mediator of pathology). 



To study the biology of tissue-resident macrophages in their natural environment, we will define (at the molecular and cellular level) the in situ response of murine and human Kupffer cells to L. donovani infection and the downstream consequences for the initiation of inflammation. We will perform comparative mRNA and miRNA profiling of human and mouse Kupffer cells, and validate potential mediators of inflammation using dynamic imaging approaches in human and murine liver. New tools will allow us to examine the function of Kupffer cells in established granulomas in mice. We will perform comparative histopathology of spleen / LN from mice and patients with VL, to determine whether the lymphoid tissue remodelling associated with parasite persistence and immunosuppression in mice is also evident in human disease, and using intra-vital imaging in combination with mice that allow cell-specific and temporal depletion and lineage tracing, we will define the involvement of mononuclear phagocytes in this process. Informed by histopathology and transcriptional profiling, we will develop new models of hepatic infection that reflect more closely the diversity of response seen in man. Likewise, we will exploit recently identified sites of cryptic infection in mice to develop a greater understanding of the mechanisms underlying post kala azar dermal leishmaniasis, mucosal disease and secondary infection. 



Collectively, the data generated in this Programme will test a number of new hypotheses related to mononuclear phagocyte function in VL, help to cross-validate existing and new mouse models and, by providing new comparative data on disease pathogenesis, increase the likelihood of effective translation of our research into new prophylactic or therapeutic interventions.</gtr:technicalSummary><gtr:fund><gtr:end>2016-04-30</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2011-01-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>1896146</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Institute of Immunobiology; Kantonsspital St.Gallen</gtr:collaboratingOrganisation><gtr:country>Switzerland, Swiss Confederation</gtr:country><gtr:description>STROMA</gtr:description><gtr:id>3AC3B69B-3936-41CA-A6EA-FF6188B3286D</gtr:id><gtr:impact>Employment of 13 ESRs and 3 ERs</gtr:impact><gtr:partnerContribution>Members of Marie Curie ITN</gtr:partnerContribution><gtr:piContribution>Co-ordinator of Marie Curie Integrated Training Network</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Institute for Endemic Diseases IEND</gtr:collaboratingOrganisation><gtr:country>Sudan, Republic of</gtr:country><gtr:description>PKDL Sudan</gtr:description><gtr:id>BB0E63E4-BF74-4E70-BDC0-1EE546B54C97</gtr:id><gtr:impact>Grant applications pending</gtr:impact><gtr:partnerContribution>Histopathology of PKDL and vaccine development</gtr:partnerContribution><gtr:piContribution>Histopathology of PKDL and vaccine development</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Manchester</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Faculty of Life Sciences</gtr:department><gtr:description>MRC Tissue Remodeling and Fibrosis Research Consortium</gtr:description><gtr:id>51680128-A1FF-4D9E-81C0-08D6E8C36F52</gtr:id><gtr:impact>Networking meetings</gtr:impact><gtr:partnerContribution>None to date</gtr:partnerContribution><gtr:piContribution>Multiple partner (`30) across UK linked to mouse phenotyping programme at Mary Lyons Centre</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Pharmidex</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Pharmidex</gtr:description><gtr:id>676DBF74-A99A-450E-AB8B-A88749EB4BAC</gtr:id><gtr:impact>Successful Phase 2 CRACKIT Challenge Award</gtr:impact><gtr:partnerContribution>Drug PKPD evaluation from Pharmidex</gtr:partnerContribution><gtr:piContribution>SME partner for Phase 1 and 2 CRACKIT Challenge awards. Management and immunology from York</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Milenia Biotec GmbH</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>STROMA</gtr:description><gtr:id>EC19D731-2E27-4023-B99C-443C7B81D83E</gtr:id><gtr:impact>Employment of 13 ESRs and 3 ERs</gtr:impact><gtr:partnerContribution>Members of Marie Curie ITN</gtr:partnerContribution><gtr:piContribution>Co-ordinator of Marie Curie Integrated Training Network</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Sim Omics</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>SimOmics</gtr:description><gtr:id>505103DF-2EF9-42B0-9814-6B45D6746342</gtr:id><gtr:impact>Successful Phase 2 CRACKIT Challenge award</gtr:impact><gtr:partnerContribution>They provide computational and software development expertise</gtr:partnerContribution><gtr:piContribution>SME collaborator in Phase 1 and 2 CRACKIT Challenge awards. Management and immunology provided by York</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Erasmus University Rotterdam (Erasmus Universitair Medisch Centrum EUR)</gtr:collaboratingOrganisation><gtr:country>Netherlands, Kingdom of the</gtr:country><gtr:department>University Medical Center</gtr:department><gtr:description>STROMA</gtr:description><gtr:id>E068CEF4-ED77-4C1F-B1DB-43C0B888825F</gtr:id><gtr:impact>Employment of 13 ESRs and 3 ERs</gtr:impact><gtr:partnerContribution>Members of Marie Curie ITN</gtr:partnerContribution><gtr:piContribution>Co-ordinator of Marie Curie Integrated Training Network</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Federal University of Pelotas (UFPel)</gtr:collaboratingOrganisation><gtr:country>Brazil, Federative Republic of</gtr:country><gtr:description>VL Brazil (Newton)</gtr:description><gtr:id>E949FC51-8638-4D95-8CC7-690714F3C3E5</gtr:id><gtr:impact>None to date</gtr:impact><gtr:partnerContribution>access to clinical samples and prospects for new clinical research programs</gtr:partnerContribution><gtr:piContribution>Newton CONFAP funded collaborative award (PI UK Mottram York); input into experimental design</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Strasbourg</gtr:collaboratingOrganisation><gtr:country>France, French Republic</gtr:country><gtr:department>Immunology</gtr:department><gtr:description>STROMA</gtr:description><gtr:id>E3518D62-50AB-4294-BBE8-BE7386C32AF4</gtr:id><gtr:impact>Employment of 13 ESRs and 3 ERs</gtr:impact><gtr:partnerContribution>Members of Marie Curie ITN</gtr:partnerContribution><gtr:piContribution>Co-ordinator of Marie Curie Integrated Training Network</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Silence Therapeutics</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Silence</gtr:description><gtr:id>81656AC4-D000-4277-A5C5-5DF62C32FC82</gtr:id><gtr:impact>none to date</gtr:impact><gtr:partnerContribution>RNAi targeting methodology</gtr:partnerContribution><gtr:piContribution>in vivo imaging</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Lisbon</gtr:collaboratingOrganisation><gtr:country>Portugal, Portuguese Republic</gtr:country><gtr:department>Institute for Molecular Medicine</gtr:department><gtr:description>STROMA</gtr:description><gtr:id>083ACB16-3241-4CBC-8722-294EAA4DB118</gtr:id><gtr:impact>Employment of 13 ESRs and 3 ERs</gtr:impact><gtr:partnerContribution>Members of Marie Curie ITN</gtr:partnerContribution><gtr:piContribution>Co-ordinator of Marie Curie Integrated Training Network</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Drugs for Neglected Diseases initiative (DNDi)</gtr:collaboratingOrganisation><gtr:country>Switzerland, Swiss Confederation</gtr:country><gtr:description>DNDi</gtr:description><gtr:id>626596A0-A96A-4544-9305-D0CA5F05C7BA</gtr:id><gtr:impact>Successful award of CRACK-IT Phase 1 grant</gtr:impact><gtr:partnerContribution>DNDi will provide clinical data to parameterise our models and provide access to new chemical entities for in vivo evaluation in models</gtr:partnerContribution><gtr:piContribution>DNDi leads international efforts in drug development for leishmaniasis. We will provide an evidence base for DNDi to design new clinical trials of leishmaniasis combination therapy</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>ProBioGen AG</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>STROMA</gtr:description><gtr:id>777585B6-BAB7-47CD-9F45-E9721EEE09E8</gtr:id><gtr:impact>Employment of 13 ESRs and 3 ERs</gtr:impact><gtr:partnerContribution>Members of Marie Curie ITN</gtr:partnerContribution><gtr:piContribution>Co-ordinator of Marie Curie Integrated Training Network</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London (UCL)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>UCL Medical School</gtr:department><gtr:description>MRC Tissue Remodeling and Fibrosis Research Consortium</gtr:description><gtr:id>12693891-177E-4018-9C7F-E63FAE2FDBA8</gtr:id><gtr:impact>Networking meetings</gtr:impact><gtr:partnerContribution>None to date</gtr:partnerContribution><gtr:piContribution>Multiple partner (`30) across UK linked to mouse phenotyping programme at Mary Lyons Centre</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Universidade Federal de Rio de Janeiro</gtr:collaboratingOrganisation><gtr:country>Brazil, Federative Republic of</gtr:country><gtr:description>UFRJ Brazil (Newton)</gtr:description><gtr:id>70476694-AD72-439D-829F-E8C7E73ECE20</gtr:id><gtr:impact>workshop on computational immunology at UFRJ; transfer of biological samples</gtr:impact><gtr:partnerContribution>collaboration on transcriptomics</gtr:partnerContribution><gtr:piContribution>Collaborative Newton award (UK PI Mottram Glasgow)</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medical Research Council (MRC)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>The Mary Lyon Centre</gtr:department><gtr:description>MRC Tissue Remodeling and Fibrosis Research Consortium</gtr:description><gtr:id>DD031D63-05F6-4DF0-B2AB-4808094FC8C6</gtr:id><gtr:impact>Networking meetings</gtr:impact><gtr:partnerContribution>None to date</gtr:partnerContribution><gtr:piContribution>Multiple partner (`30) across UK linked to mouse phenotyping programme at Mary Lyons Centre</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>London School of Hygiene and Tropical Medicine (LSHTM)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>LSHTM</gtr:description><gtr:id>77BAB436-A214-4C9B-9C8C-ED2A0464DCBC</gtr:id><gtr:impact>Award of Phase 2 CRACKIT Challenge grant</gtr:impact><gtr:partnerContribution>Drug discovery and PKPD analysis provided by LSHTM</gtr:partnerContribution><gtr:piContribution>Research collaboration on joint CRACK-IT Phase 1 and Phase 2 projects. Project management and immunology expertise provided by York</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Birmingham</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC Centre for Immune Regulation</gtr:department><gtr:description>MRC Tissue Remodeling and Fibrosis Research Consortium</gtr:description><gtr:id>DE05C419-2A6E-4BA9-97F7-87B61C51AAD1</gtr:id><gtr:impact>Networking meetings</gtr:impact><gtr:partnerContribution>None to date</gtr:partnerContribution><gtr:piContribution>Multiple partner (`30) across UK linked to mouse phenotyping programme at Mary Lyons Centre</gtr:piContribution><gtr:sector>Multiple</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Max Planck Society</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:department>Max Planck Institute of Biochemistry</gtr:department><gtr:description>STROMA</gtr:description><gtr:id>A4F581C8-A6AE-4DC5-A761-BD21E8A89CEA</gtr:id><gtr:impact>Employment of 13 ESRs and 3 ERs</gtr:impact><gtr:partnerContribution>Members of Marie Curie ITN</gtr:partnerContribution><gtr:piContribution>Co-ordinator of Marie Curie Integrated Training Network</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Zurich (Universit?t Z?rich UZH)</gtr:collaboratingOrganisation><gtr:country>Switzerland, Swiss Confederation</gtr:country><gtr:department>Institute of Oral Biology</gtr:department><gtr:description>STROMA</gtr:description><gtr:id>167295AF-8700-46A7-B4A2-019BB8C5D486</gtr:id><gtr:impact>Employment of 13 ESRs and 3 ERs</gtr:impact><gtr:partnerContribution>Members of Marie Curie ITN</gtr:partnerContribution><gtr:piContribution>Co-ordinator of Marie Curie Integrated Training Network</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>The Wellcome Trust Ltd</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Wellcome Trust Centre for Molecular Parasitology</gtr:department><gtr:description>Glasgow</gtr:description><gtr:id>77E4E511-C101-40DB-B39E-30A5CEAE7B60</gtr:id><gtr:impact>Successful Phase 2 CRACKIT Challenge award</gtr:impact><gtr:partnerContribution>Molecular parasitology expertise from Glasgow</gtr:partnerContribution><gtr:piContribution>Collaboration for Phase 1 and Phase 2 CRACKIT Challenge funding. Management and immunology from York</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Materiomics</gtr:collaboratingOrganisation><gtr:country>Netherlands, Kingdom of the</gtr:country><gtr:description>STROMA</gtr:description><gtr:id>6731DFA4-538D-49F9-B805-350AA66D44D0</gtr:id><gtr:impact>Employment of 13 ESRs and 3 ERs</gtr:impact><gtr:partnerContribution>Members of Marie Curie ITN</gtr:partnerContribution><gtr:piContribution>Co-ordinator of Marie Curie Integrated Training Network</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cybula</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Cybula</gtr:description><gtr:id>9D3D18C2-D370-4A7A-A5F3-6257A90A02DA</gtr:id><gtr:impact>Successful Phase 2 CRACKIT Challenge award</gtr:impact><gtr:partnerContribution>They provide computational, cloud data sharing and software design expertise</gtr:partnerContribution><gtr:piContribution>SME collaborator in CRACKIT Phase 1 and 2 awards. Management and immunology from York</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Institute of Post-Graduate Medical Education and Research and Seth Sukhlal Karnani Memorial Hospital</gtr:collaboratingOrganisation><gtr:country>India, Republic of</gtr:country><gtr:department>Department of Pharmacology</gtr:department><gtr:description>PKDL</gtr:description><gtr:id>419C9DE6-47A4-448F-9CBD-02D59212D729</gtr:id><gtr:impact>Publications in preparation</gtr:impact><gtr:partnerContribution>Collaborative research on histopathology of PKDL</gtr:partnerContribution><gtr:piContribution>Collaborative research on histopathology of PKDL</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Festival of Science 2015</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>42326EEC-7438-4223-8A5E-8DE27B63A06E</gtr:id><gtr:impact>Attended stand at festival of Science communicating work on leishmaniasis and computational modelling</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Festival of Science 2014</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>CF5787CC-A0EA-4A35-93C0-1BA2CAE8EFB6</gtr:id><gtr:impact>Stand and visual displays on research program and NC3Rs activity in pavilion erected in centre of York. Footfall of approx. 300, with children playing with robots and adults learning about simulations of infectious disease as a means for reducing animal usage in drug development. High level of public engagement through curiosity driven play and question with subsequent discussion. Increased awareness of neglected tropical diseases

Follow up engagement activities planned and subsequently delivered</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://yorkfestivalofideas.com/2014/</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Tour Grand Depart</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>A9BFD986-16F2-4511-AF00-A44711EE9BD1</gtr:id><gtr:impact>NC3Rs stand at the University of York exhibition pavilion at the Tour de France Grand depart allowed exposure of 3Rs principles and the work funded by The CRACKIT Challenge to be highlighted to ~2000 attendees, including demonstration of robot simulators of immunity. The case for research and development for fighting neglected tropical disease was also made . Throughout the day, these pics prompted questions and curiosity from all age groups.

Increased awareness by many of the major issues in the fight against neglected diseases and how concerted efforts by interdisciplinary teams can address these, with additional 3Rs added value.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.york.ac.uk/computational-immunology/news/ycilattdf/</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>YorNight 2014</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>2D9CD824-9F61-4CCC-9042-B9FFFE09EF3A</gtr:id><gtr:impact>Stand and visual displays on research program and NC3Rs activity in pavilion in centre of York. Footfall of approx. 300, with children playing with robots and adults learning about simulations of infectious disease as a means for reducing animal usage in drug development. High level of public engagement through curiosity driven play and question with subsequent discussion. Increased awareness of neglected tropical diseases

Many questions and responses indicating public awareness and understanding of why animals are used in research and ongoing &amp;pound;Rs research programs in York and elsewhere</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.york.ac.uk/cii/news/markcoles-sept14/</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>EU Researchers Night 2015</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>32489DF4-D2C9-4B91-A613-3F83DC72AD53</gtr:id><gtr:impact>Attended stand at EU Researchers Night, communicating work on leishmaniasis and computational modelling</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Festival of Science</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>6F08A325-7F44-4FE9-9471-F22BB70B36A7</gtr:id><gtr:impact>200+ visitors to a city centre exhibition on research on chronic diseases

increased profile for MRC related research</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Poster Presentation</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2012,2013</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>2300000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Senior Investigator Award</gtr:description><gtr:end>2019-12-02</gtr:end><gtr:fundingOrg>The Wellcome Trust Ltd</gtr:fundingOrg><gtr:fundingRef>32470</gtr:fundingRef><gtr:id>7C8CF542-4E4F-4EB0-BA1E-B3278AC67D84</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>30000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome ISSF</gtr:description><gtr:end>2013-03-02</gtr:end><gtr:fundingOrg>University of York</gtr:fundingOrg><gtr:id>6AED0433-EC79-47C0-913A-8F3C6AA6BB74</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>996000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>CRACK-IT Phase 2</gtr:description><gtr:end>2017-12-02</gtr:end><gtr:fundingOrg>National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs)</gtr:fundingOrg><gtr:id>8375D4FE-7E04-43FC-BE27-BD53C1C6D938</gtr:id><gtr:sector>Private</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>900000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:department>Seventh Framework Programme (FP7)</gtr:department><gtr:description>STROMA</gtr:description><gtr:end>2015-12-02</gtr:end><gtr:fundingOrg>Community Research and Development Information Service (CORDIS)</gtr:fundingOrg><gtr:fundingRef>289720</gtr:fundingRef><gtr:id>71363397-C5D6-4C5D-9F87-6B8CEBC685A5</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>465281</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>RCUK GCRF Foundation Award</gtr:description><gtr:end>2019-03-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>MR/P024661/1</gtr:fundingRef><gtr:id>CF8ABFFE-3978-4227-AF4A-2BBA9A13E8A9</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2017-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1600000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Translation Award</gtr:description><gtr:end>2020-10-02</gtr:end><gtr:fundingOrg>The Wellcome Trust Ltd</gtr:fundingOrg><gtr:fundingRef>WT108518MA</gtr:fundingRef><gtr:id>7459FD34-8A92-456E-B3E7-8FAD350379E3</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>100000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>CRACK-IT Phase 1</gtr:description><gtr:end>2014-06-02</gtr:end><gtr:fundingOrg>National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs)</gtr:fundingOrg><gtr:id>72A6FC1E-2D56-40DA-B156-A640DC3E5840</gtr:id><gtr:sector>Private</gtr:sector><gtr:start>2013-12-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>30000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome ISSF</gtr:description><gtr:end>2014-01-02</gtr:end><gtr:fundingOrg>University of York</gtr:fundingOrg><gtr:id>CABC25E9-65E7-4C51-83DC-1A6B8D293A79</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-06-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>Therapeutic adenoviral vectored leishmaniasis vaccine.
Re-fundd for Phase2 trials by Wellcome Trust in 2015</gtr:description><gtr:id>857A5665-0B5A-4A2D-A07E-35583B61F08D</gtr:id><gtr:impact>safety and first human immunogenicity data on leishmanial antigens</gtr:impact><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>LEISH1</gtr:title><gtr:type>Therapeutic Intervention - Vaccines</gtr:type><gtr:ukcrnIsctnId>EudraCT 2012-005596-14</gtr:ukcrnIsctnId><gtr:yearDevCompleted>2013</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>Phase IIa trial of therapeutic vaccine in Sudan</gtr:description><gtr:id>8E1D06B2-EFB5-4C18-9B5C-7D62A65AD8DE</gtr:id><gtr:impact>Additional funding being sought for prophylactic vaccine development.</gtr:impact><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>LEISH2a</gtr:title><gtr:type>Therapeutic Intervention - Vaccines</gtr:type><gtr:ukcrnIsctnId>EudraCT 2016-000369-22</gtr:ukcrnIsctnId><gtr:url>http://www.wellcome.ac.uk/Funding/Innovations/Funded-projects/Vaccine/index.htm</gtr:url><gtr:yearDevCompleted>2014</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs><gtr:researchDatabaseAndModelOutput><gtr:description>A pilot version of a leishmaniasis drug - immune simulator for reducing animal usage in leishmaniasis drug development</gtr:description><gtr:id>EB74AF28-9881-47BE-9161-409A728C8373</gtr:id><gtr:impact>Award of CRACK IT Phase 2 funding from NC3Rs</gtr:impact><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>LeishSim v1.1</gtr:title><gtr:type>Computer model/algorithm</gtr:type></gtr:researchDatabaseAndModelOutput></gtr:researchDatabaseAndModelOutputs><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Transcriptomes of Kupffer cells isolated from naive and infected mice: E-MEXP-3877</gtr:description><gtr:id>D9DF4ADB-E75B-492F-A31D-87F60C20C994</gtr:id><gtr:impact>none to date</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Macrophage transcriptomes</gtr:title><gtr:type>Biological samples</gtr:type><gtr:url>http://www.ebi.ac.uk/arrayexpress/</gtr:url><gtr:yearFirstProvided>2013</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/52E9D44F-C223-44CF-A154-E644D5E18882"><gtr:id>52E9D44F-C223-44CF-A154-E644D5E18882</gtr:id><gtr:title>Regiospecific methylation of a dietary flavonoid scaffold selectively enhances IL-1? production following Toll-like receptor 2 stimulation in THP-1 monocytes.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/ea92bb3cfcf734eb0f5591f7c788e888"><gtr:id>ea92bb3cfcf734eb0f5591f7c788e888</gtr:id><gtr:otherNames>Lim EK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/3E7CF9C7-3AFC-4CD3-969A-F17B27A8B238"><gtr:id>3E7CF9C7-3AFC-4CD3-969A-F17B27A8B238</gtr:id><gtr:title>Salmonella Typhi Lipopolysaccharide O-antigen Modifications Impact on Serum Resistance and Antibody Recognition.</gtr:title><gtr:parentPublicationTitle>Infection and immunity</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/83b6e9b840f7871286f6499f483de7e4"><gtr:id>83b6e9b840f7871286f6499f483de7e4</gtr:id><gtr:otherNames>Kintz E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0019-9567</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/54F02CF7-B080-4CDF-A451-672AC9F74CE9"><gtr:id>54F02CF7-B080-4CDF-A451-672AC9F74CE9</gtr:id><gtr:title>Post kala-azar dermal leishmaniasis: an unresolved mystery.</gtr:title><gtr:parentPublicationTitle>Trends in parasitology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/46cc3e007523b7dfe1100dfc6505adb9"><gtr:id>46cc3e007523b7dfe1100dfc6505adb9</gtr:id><gtr:otherNames>Mukhopadhyay D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1471-4922</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/947AF359-D3F0-4B3B-8FAD-D0671EE27C90"><gtr:id>947AF359-D3F0-4B3B-8FAD-D0671EE27C90</gtr:id><gtr:title>In vivo imaging of systemic transport and elimination of xenobiotics and endogenous molecules in mice.</gtr:title><gtr:parentPublicationTitle>Archives of toxicology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/eed35c4bf1b2535fb903527ae1158e77"><gtr:id>eed35c4bf1b2535fb903527ae1158e77</gtr:id><gtr:otherNames>Reif R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0340-5761</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/2485DFBD-8494-4870-A28D-1BA09A5D1AFC"><gtr:id>2485DFBD-8494-4870-A28D-1BA09A5D1AFC</gtr:id><gtr:title>Critical roles for LIGHT and its receptors in generating T cell-mediated immunity during Leishmania donovani infection.</gtr:title><gtr:parentPublicationTitle>PLoS pathogens</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/0d5c3c61b5b0f65d9dbb4256db8c9a59"><gtr:id>0d5c3c61b5b0f65d9dbb4256db8c9a59</gtr:id><gtr:otherNames>Stanley AC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1553-7366</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/859AB64A-2CF0-40D6-BA06-6AB70D3686B6"><gtr:id>859AB64A-2CF0-40D6-BA06-6AB70D3686B6</gtr:id><gtr:title>Bone marrow-derived and resident liver macrophages display unique transcriptomic signatures but similar biological functions.</gtr:title><gtr:parentPublicationTitle>Journal of hepatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/3f74cb360370ab50a1ef10a822c94104"><gtr:id>3f74cb360370ab50a1ef10a822c94104</gtr:id><gtr:otherNames>Beattie L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0168-8278</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/BF8D8C3C-3042-4B51-B9AC-655F1BA6522B"><gtr:id>BF8D8C3C-3042-4B51-B9AC-655F1BA6522B</gtr:id><gtr:title>Cervico-vaginal immunoglobulin G levels increase post-ovulation independently of neutrophils.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/8f44c179ff39a89af1537772d1b1301e"><gtr:id>8f44c179ff39a89af1537772d1b1301e</gtr:id><gtr:otherNames>Schaefer K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/C6CE5DB4-BD50-4A91-BBEE-B96517C3CCCC"><gtr:id>C6CE5DB4-BD50-4A91-BBEE-B96517C3CCCC</gtr:id><gtr:title>The neurotrophic receptor Ntrk2 directs lymphoid tissue neovascularization during Leishmania donovani infection.</gtr:title><gtr:parentPublicationTitle>PLoS pathogens</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/d7b016fb6b1088ac1954c5f10150b029"><gtr:id>d7b016fb6b1088ac1954c5f10150b029</gtr:id><gtr:otherNames>Dalton JE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1553-7366</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/7A64F899-F083-4A4C-9B30-75816D369C73"><gtr:id>7A64F899-F083-4A4C-9B30-75816D369C73</gtr:id><gtr:title>Therapeutic vaccination with recombinant adenovirus reduces splenic parasite burden in experimental visceral leishmaniasis.</gtr:title><gtr:parentPublicationTitle>The Journal of infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f90ac9a971753de9cffe88e2eafa0a30"><gtr:id>f90ac9a971753de9cffe88e2eafa0a30</gtr:id><gtr:otherNames>Maroof A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0022-1899</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/58EC7AEF-9086-47F9-A76F-0333C9DCB1EC"><gtr:id>58EC7AEF-9086-47F9-A76F-0333C9DCB1EC</gtr:id><gtr:title>Stromal cell induction of regulatory dendritic cells.</gtr:title><gtr:parentPublicationTitle>Frontiers in immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/dc84d5bfd6bb01e33e7e4cac6e581f8f"><gtr:id>dc84d5bfd6bb01e33e7e4cac6e581f8f</gtr:id><gtr:otherNames>Owens BM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1664-3224</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/E9F40893-3737-4851-98F0-CEA40A340998"><gtr:id>E9F40893-3737-4851-98F0-CEA40A340998</gtr:id><gtr:title>M2 Polarization of Monocytes-Macrophages Is a Hallmark of Indian Post Kala-Azar Dermal Leishmaniasis.</gtr:title><gtr:parentPublicationTitle>PLoS neglected tropical diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/46cc3e007523b7dfe1100dfc6505adb9"><gtr:id>46cc3e007523b7dfe1100dfc6505adb9</gtr:id><gtr:otherNames>Mukhopadhyay D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1935-2727</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/D7D5246C-4E27-40BB-A043-564A64026496"><gtr:id>D7D5246C-4E27-40BB-A043-564A64026496</gtr:id><gtr:title>Case study for a vaccine against leishmaniasis.</gtr:title><gtr:parentPublicationTitle>Vaccine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/9a9902acb51cc8538c75a53f1de68286"><gtr:id>9a9902acb51cc8538c75a53f1de68286</gtr:id><gtr:otherNames>Alvar J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0264-410X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/2C199289-A677-4C2F-834F-E0E48DFD878B"><gtr:id>2C199289-A677-4C2F-834F-E0E48DFD878B</gtr:id><gtr:title>A transcriptomic network identified in uninfected macrophages responding to inflammation controls intracellular pathogen survival.</gtr:title><gtr:parentPublicationTitle>Cell host &amp; microbe</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/3f74cb360370ab50a1ef10a822c94104"><gtr:id>3f74cb360370ab50a1ef10a822c94104</gtr:id><gtr:otherNames>Beattie L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1931-3128</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/584873C3-860E-453D-AD21-DE6532B5A595"><gtr:id>584873C3-860E-453D-AD21-DE6532B5A595</gtr:id><gtr:title>Functional complexity of the Leishmania granuloma and the potential of in silico modeling.</gtr:title><gtr:parentPublicationTitle>Frontiers in immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/e3e7405347d7549210cf6f7e01ad666b"><gtr:id>e3e7405347d7549210cf6f7e01ad666b</gtr:id><gtr:otherNames>Moore JW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1664-3224</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/3A60EA57-77F0-4A41-83E3-4E7DC6F097C8"><gtr:id>3A60EA57-77F0-4A41-83E3-4E7DC6F097C8</gtr:id><gtr:title>Single dose novel Salmonella vaccine enhances resistance against visceralizing L. major and L. donovani infection in susceptible BALB/c mice.</gtr:title><gtr:parentPublicationTitle>PLoS neglected tropical diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/627fe3f5c5083a1e7dad400696d97ed9"><gtr:id>627fe3f5c5083a1e7dad400696d97ed9</gtr:id><gtr:otherNames>Schroeder J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1935-2727</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/ACD87E5F-D279-4335-8BBC-B7B43E229365"><gtr:id>ACD87E5F-D279-4335-8BBC-B7B43E229365</gtr:id><gtr:title>B cell: T cell interactions occur within hepatic granulomas during experimental visceral leishmaniasis.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/e3e7405347d7549210cf6f7e01ad666b"><gtr:id>e3e7405347d7549210cf6f7e01ad666b</gtr:id><gtr:otherNames>Moore JW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/3D764AE9-F213-4D49-8081-39A34A5DCE1A"><gtr:id>3D764AE9-F213-4D49-8081-39A34A5DCE1A</gtr:id><gtr:title>Functional analysis of Leishmania cyclopropane fatty acid synthetase.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/ee43912ff375f45704704105ce9b8cf3"><gtr:id>ee43912ff375f45704704105ce9b8cf3</gtr:id><gtr:otherNames>Oyola SO</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/7519AEF2-671B-43B3-A22B-DE2EE285B2B5"><gtr:id>7519AEF2-671B-43B3-A22B-DE2EE285B2B5</gtr:id><gtr:title>Compartment-specific remodeling of splenic micro-architecture during experimental visceral leishmaniasis.</gtr:title><gtr:parentPublicationTitle>The American journal of pathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/64f36726b2fdda200dbb3275feba4d5c"><gtr:id>64f36726b2fdda200dbb3275feba4d5c</gtr:id><gtr:otherNames>Yurdakul P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0002-9440</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/35569350-EBC4-472B-B90C-C3EEED0B04C6"><gtr:id>35569350-EBC4-472B-B90C-C3EEED0B04C6</gtr:id><gtr:title>A Petri net model of granulomatous inflammation: implications for IL-10 mediated control of Leishmania donovani infection.</gtr:title><gtr:parentPublicationTitle>PLoS computational biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/4bc5e237f9d8a1c9e7af5a6197efaa0c"><gtr:id>4bc5e237f9d8a1c9e7af5a6197efaa0c</gtr:id><gtr:otherNames>Albergante L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1553-734X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/EC04AEBB-18B6-4E60-85F3-CB2216011EAE"><gtr:id>EC04AEBB-18B6-4E60-85F3-CB2216011EAE</gtr:id><gtr:title>Reduced expression of monocyte CD200R is associated with enhanced proinflammatory cytokine production in sarcoidosis.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/d2e1aa2b7046848d19308343dbc23e52"><gtr:id>d2e1aa2b7046848d19308343dbc23e52</gtr:id><gtr:otherNames>Fraser SD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/6D433E00-54B7-447A-ABA2-E789BC1719CA"><gtr:id>6D433E00-54B7-447A-ABA2-E789BC1719CA</gtr:id><gtr:title>IRF7 regulates TLR2-mediated activation of splenic CD11c(hi) dendritic cells.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/dc84d5bfd6bb01e33e7e4cac6e581f8f"><gtr:id>dc84d5bfd6bb01e33e7e4cac6e581f8f</gtr:id><gtr:otherNames>Owens BM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/8853B8D3-1E07-49A1-B090-46C076FB9496"><gtr:id>8853B8D3-1E07-49A1-B090-46C076FB9496</gtr:id><gtr:title>Visceral leishmaniasis: immunology and prospects for a vaccine.</gtr:title><gtr:parentPublicationTitle>Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/7c89aed5fb181cf2634c915b0d4e12c9"><gtr:id>7c89aed5fb181cf2634c915b0d4e12c9</gtr:id><gtr:otherNames>Kaye PM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1198-743X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/4EFBAC68-9EE8-4024-9375-0AFB8C8E5C0D"><gtr:id>4EFBAC68-9EE8-4024-9375-0AFB8C8E5C0D</gtr:id><gtr:title>Leishmaniasis: complexity at the host-pathogen interface.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Microbiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/14a4d75bdfa47b148a6a4d1e5f14c5bc"><gtr:id>14a4d75bdfa47b148a6a4d1e5f14c5bc</gtr:id><gtr:otherNames>Kaye P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1740-1526</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/E2EEFF05-6E98-4077-AD20-E76718DE358D"><gtr:id>E2EEFF05-6E98-4077-AD20-E76718DE358D</gtr:id><gtr:title>Building confidence in quantitative systems pharmacology models: An engineer's guide to exploring the rationale in model design and development.</gtr:title><gtr:parentPublicationTitle>CPT: pharmacometrics &amp; systems pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/4ab83f0f6a61728cc318342d2c4a35d9"><gtr:id>4ab83f0f6a61728cc318342d2c4a35d9</gtr:id><gtr:otherNames>Timmis J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2163-8306</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/C6382774-3226-452D-B8D3-537FB6406B4D"><gtr:id>C6382774-3226-452D-B8D3-537FB6406B4D</gtr:id><gtr:title>IL-10-producing Th1 cells and disease progression are regulated by distinct CD11c? cell populations during visceral leishmaniasis.</gtr:title><gtr:parentPublicationTitle>PLoS pathogens</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/dc84d5bfd6bb01e33e7e4cac6e581f8f"><gtr:id>dc84d5bfd6bb01e33e7e4cac6e581f8f</gtr:id><gtr:otherNames>Owens BM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1553-7366</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/17EA8C78-1480-4714-9C43-FD56014DDE22"><gtr:id>17EA8C78-1480-4714-9C43-FD56014DDE22</gtr:id><gtr:title>Leishmania-host interactions: what has imaging taught us?</gtr:title><gtr:parentPublicationTitle>Cellular microbiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/3f74cb360370ab50a1ef10a822c94104"><gtr:id>3f74cb360370ab50a1ef10a822c94104</gtr:id><gtr:otherNames>Beattie L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1462-5814</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/E34BACFC-A65C-4670-88FF-F13B7A67E443"><gtr:id>E34BACFC-A65C-4670-88FF-F13B7A67E443</gtr:id><gtr:title>IL-7-producing stromal cells are critical for lymph node remodeling.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/14b02ced7323260e301436f30d73db18"><gtr:id>14b02ced7323260e301436f30d73db18</gtr:id><gtr:otherNames>Onder L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/6AD9AFB1-1FC0-404F-9DFB-3EC06A562003"><gtr:id>6AD9AFB1-1FC0-404F-9DFB-3EC06A562003</gtr:id><gtr:title>CD4+ Recent Thymic Emigrants Are Recruited into Granulomas during Leishmania donovani Infection but Have Limited Capacity for Cytokine Production.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/e3e7405347d7549210cf6f7e01ad666b"><gtr:id>e3e7405347d7549210cf6f7e01ad666b</gtr:id><gtr:otherNames>Moore JW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/4EEA8299-5792-49EB-8EA6-EE9FC25F9ED3"><gtr:id>4EEA8299-5792-49EB-8EA6-EE9FC25F9ED3</gtr:id><gtr:title>Lessons from other diseases: granulomatous inflammation in leishmaniasis.</gtr:title><gtr:parentPublicationTitle>Seminars in immunopathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/7c89aed5fb181cf2634c915b0d4e12c9"><gtr:id>7c89aed5fb181cf2634c915b0d4e12c9</gtr:id><gtr:otherNames>Kaye PM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1863-2297</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/68180D78-4562-4F9D-B7C9-5748D4A05BBD"><gtr:id>68180D78-4562-4F9D-B7C9-5748D4A05BBD</gtr:id><gtr:title>Bile canalicular dynamics in hepatocyte sandwich cultures.</gtr:title><gtr:parentPublicationTitle>Archives of toxicology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/eed35c4bf1b2535fb903527ae1158e77"><gtr:id>eed35c4bf1b2535fb903527ae1158e77</gtr:id><gtr:otherNames>Reif R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0340-5761</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/C6D22228-1E12-4066-92A4-48D0F50E86B6"><gtr:id>C6D22228-1E12-4066-92A4-48D0F50E86B6</gtr:id><gtr:title>Tissue requirements for establishing long-term CD4+ T cell-mediated immunity following Leishmania donovani infection.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/94f5de1eca95833fd8a04e31b1c72abb"><gtr:id>94f5de1eca95833fd8a04e31b1c72abb</gtr:id><gtr:otherNames>Bunn PT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G1000230</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>